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Abstract 
Background and aims: to develop a prognostic mathematical model for risk of 
microangiopathy in patients with diabetes mellitus type 1 (T1DM). Materials and 
methods: 62 T1DM patients were divided into 2 groups according to НвА1с level: group 
1 (n=18) with НвА1с ≤ 7.0% and group 2 (n=44) with НвА1с > of 7.0%. HbA1c, C-
peptide, blood creatinine, estimated glomerular filtration rate (eGFR) CKD-EPI, first 
morning urinary albumin excretion (AU) were determined. Blood glucose levels were 
conducted by CGMS (Continuous Glucose Monitoring System). All patients were followed 
for 3 months. Rank correlation method was used. Results: We established the direct 
correlation between HbA1c the AU level ρ=0.29 (р<0.016) at the beginning and ρ=0.4 
(р=0.021) after 3 months. AU level has a direct correlation with blood glucose range, at 
the beginning ρ=0.51 (р<0.001) and after 3 months ρ=0.48 (р=0.004) visits. We made 
the mathematical description of this dependence. Each additional unit of blood glucose 
range is accompanied by increasing an average level AU level by 0.4816 mg/l. 
Conclusion: our mathematical equation of dependence between AU level and blood 
glucose range gives the opportunities to predict diabetic kidney disease progression in 
T1DM patients. 
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Background and aims 
Today diabetes mellitus (DM) is one of the 
leading medical and social problems. The World 
Health Organization (WHO) informs that the 
number of patients with DM is increasing 
annually. Presently, there are about 422 million 
people with diabetes in the world [1]. The 
overall incidence of DM has almost doubled 
since 1980, rising from 4.7% to 8.5%. The 
International Diabetes Federation (IDF) 
identifies that the total number of DM patients 
will reach 629 million by 2045 [2]. Patients with 
type 1 diabetes mellitus (T1DM) account for 5-
10% of the total cases of DM. The prevalence of 
T1DM in children under 15 years is increasing 
all over the world with the average annual 
growth about 3%. Annually, 132600 new 
medical cases of T1DM are registered among 
young people under the age of 20 years old [2,3].  
Microangiopathy is one of the major 
complications of T1DM. The pathophysiology of 
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diabetic microangiopathy is multifactorial and 
caused by hyperglycemia. There are a few 
pathological processes, which it forms 
microvascular complications: non-enzymatic 
glycation of proteins, the polyol pathway 
activation, glucose toxicity and the violation of 
glycosaminoglycan exchange [4]. Chronic 
hyperglycemia promotes endothelial 
dysfunction, which leads to formation of chronic 
diabetic complications [5,6]. Diabetic 
microangiopathy is the main cause of the 
patient's disability and mortality. That's why 
diabetic microangiopathy defines the disease 
course and prognosis [5,7]. 
The aim of the study: to develop a 
prognostic mathematical model for risk of 
microangiopathy, a in patients with type 1 DM. 
Materials and methods 
62 T1DM patients were enrolled in this 
study, including 25 men (40.32%) and women - 
37 (57.68%). Average age was 31.5 (24.0; 39.0). 
The study was conducted in the Endocrinology 
Department of University Clinic of 
«Dnepropetrovsk Medical Academy», 2016-
2017. The duration of the disease was 11.0 (5.0; 
18.0) years and the body mass index (BMI) 
23.06 (20.81: 24.08) kg/m
2
. All patients used 
basic-bolus insulin therapy with the insulin daily 
dose 45 (35.0; 58.0) units. 
Exclusion criteria: Type 2 DM; diabetic 
ketoacidosis at the moment of inclusion; 
secondary DM; body mass index (BMI) > 40 
kg/m
2
; diabetic proliferative retinopathy; chronic 
kidney disease IIIB - V; diabetic foot (II Wagner 
class and above); heart failure III / IV by the 
New York Heart Association (NYHA); 
congenital and acquired heart disease; acute 
coronary syndrome, acute ischemic stroke and 
transient ischemic attack; exacerbation of 
accompanying chronic diseases; acute illness; 
pregnancy. 
All the patients signed informed consent 
form, approved by the local Ethics Committee. 
The procedures performed in study involving 
human participants were in accordance with the 
1964 Helsinki declaration and its later 
amendments or comparable ethical standards  
The diagnosis of T1DM was made according 
to American Diabetes Association (ADA) 
criteria - 2016 [8]. 
The C-peptide, HbA1c, blood creatinine, the 
first morning urinary albumin (AU) were 
determined at the beginning and 3 months after 
treatment modification. C-peptide was 
determined on the electrochemiluminescence 
automatic immunochemical analyzer COBAS e 
411, Roche Diagnostics GmbH & Hitachi, 
Japan, 2012. The blood creatinine level, HbA1c 
and AU were determined using automatic 
biochemical analyzer SAPPHIRE 400, Tokio 
Boeki, Japan, 2009. eGFR was calculated 
according to CKD-EPI formula. Long-term 
monitoring of blood glucose levels was 
conducted by using the system CGMS 
(Continuous Glucose Monitoring System, 
Medtronic MiniMed, USA). This system detects 
electrical signals every 10 seconds and 
transforming them in glucose values every 5 
minutes. Hypoglycemia was considered as an 
episode of lower blood glucose level less than 
3.9 mmol/l according to ADA criteria [8]. The 
maximum and minimum blood glucose levels 
and the blood glucose range (maximum minus 
minimum blood glucose values due to CGMS), 
were considered. 
Patients were divided into 2 groups 
according to the level НвА1с: Group 1-HbA1c 
≤7.0 % (n=18), Group 2 – HbA1c>7.0 % (n=44). 
10 healthy age- and sex-matched controls were 
included in this study. The treatment 
modification was performed in patients with 
poor glucose control (HbA1c higher, than 
individual target level and/or frequent 
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hypoglycemic conditions). It included changes of 
insulin doses, treatment regimen, lifestyle 
modification and regular self-monitoring of 
blood glucose. 
Statistical analysis 
The data were analyzed using Microsoft 
Excel (Office Home Business) with add-on 
AtteStat and the software STATISTICA 6.1 
(StatSoftInc.). The data were described by 
median and quarterly ranges (Me (25%; 75%). 
The Spearman rank correlation coefficient (ρ) 
was calculated. Correlation coefficient in range 
0.7 ≤ | ρ | <1 shows the strong correlation, in 
range 0.3 ≤ | ρ | < 0.7 shows the average 
correlation, and in range 0 < | ρ | < 0.3 – a weak 
correlation. 
 
Results 
The groups of patients were compared by 
age and seх, duration of the disease, main 
anthropometric indexes, insulin daily dose, 
eGFR and the AU level. In group 1 the average 
HbA1c was 6.85 (6.65, 7) %, in group 2 – 10.95 
(9.4, 12) %, in control group – 4.35 (4.05; 4.7) 
%. The moderately increased AU was 
determined in 27.78% patients in group 1 and 
54.55% patients in group 2. The severely 
increased albuminuria AU was defined in 5.56% 
patients in group 1 and 4.55% patients in group 
2.  
T1DM patients had significantly higher 
HbA1c, creatinine, eGFR, AU levels, and 
significant lower C-peptide level (р<0,001) 
compared to control. These trends are stored 
after 3 months (Table 1).  
Table 1. Laboratory data in study groups (Median and interquartile range - Me (25%; 75%)). 
Parameters 
Group 1 
(n=18) 
Group 2 
(n=44) 
T1DM (n=62) 
Control 
group 
(n=10) 
Comparison 
between groups 
р pо-к 
HbA1c, % 
beginning 
6.85 (6.65; 7) 
10.95 (9.4; 
12) 
9.8 (7.4; 11.2) 
4,35 (4,05; 
4,7) 
р<0.001 
p1-к=0.398 
p2-к<0.001 
p1-2<0.001 
<0.001 
HbA1c, % 
after 3 months 
7 (6.7; 8.08) 9.2 (7.6; 10) 8,5 (7; 9.7) 
р<0.001 
p1-к=0.133 
p2-к<0.001 
p1-2=0.117 
<0.001 
р between visits. * 0.173 0.081 0.104 - - - 
C-peptide ng/ml 
0.02 (0.01; 
0.65) 
0.01 (0.01; 
0.1) 
0.01 (0.01; 0.15) 
2.85 (2.6; 
3.45) 
р<0.001 
p1-к=0.002 
p2-к<0.001 
p1-2=0.670 
<0.001 
Creatinine, 
μmol / ml 
beginning 
91.12 (83.06; 
95.87) 
96 (89.9; 
103.97) 
94.6 (86.12; 
103.35) 
68.5 (66.5; 
84) 
р<0.001 
p1-к=0.033 
p2-к<0.001 
p1-2=0.193 
<0.001 
Creatinine,  
μmol / ml 
after 3 months 
96 (94.91; 
100.24) 
91.16 
(86.82; 
99.05) 
94.91 (88.99; 
99.6) 
р<0.001 
p1-к=0.001 
p2-к=0.002 
p1-2=0.735 
<0.001 
р between visits * 0.237 0.686 0.882 - - - 
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Table 1. Conitnued. 
Parameters 
Group 1 
(n=18) 
Group 2 
(n=44) 
T1DM (n=62) 
Control 
group 
(n=10) 
Comparison 
between groups 
р pо-к 
eGFR , 
ml / min / 1. 73 m²  
beginning 
79 (71; 86) 75 (66; 85) 76 (67; 85) 
108,5 (105; 
111) 
р<0.001 
p1-к=0.003 
p2-к<0.001 
p1-2=1.000 
<0.001 
eGFR , 
ml / min / 1. 73 m²  
after 3 months 
76 (65; 83) 74 (69; 80) 75 (69; 80) 
р<0.001 
p1-к=0.005 
p2-к<0.001 
p1-2=1.000 
<0.001 
р between visits * 0.176 0.225 0.954 - - - 
AU, mg/l 
beginning 
23.45 (15.4; 
38.9) 
34.4 (16.8; 
51.2) 
30,3 (16.8; 44.7) 
6.7 (5.5; 9.4) 
р<0.001 
p1-к=0.006 
p2-к<0.001 
p1-2=0.881 
<0.001 
AU, mg/l 
after 3 months 
20.9 (12.2; 
31.6) 
24 (19.9; 
47.6) 
22.8 (13,8; 43.7) 
р<0.001 
p1-к=0.025 
p2-к<0.001 
p1-2=1.000 
<0.001 
р between visits. * 0.866 0.043 0.353 - - - 
Notes. р – differences between groups according to the non-parametric dispersion analysis of Kruskal-Wallis (KW-H); 
aposteriori comparisons – according to the Dunn criteria, pairwise – by Mann-Whitney (U): 
p1-k - between group 1 and control group; 
p2-k – between group 2 and control group; 
ro-k – between the main group and the control group; 
p1-2 – between group 1 and group 2  
*- p in the dynamics between the beginning and after 3 months according to the Wilcoxon test. 
 
Due to CGMS, both groups separately and 
major groups generally have significantly higher 
maximum glucose levels and blood glucose 
range compared with the control group. 
(р<0.001). There were no statistically significant 
differences between groups (Table 2). 
Table 2. Blood glucose levels in study groups, mmol/l (Median and interquartile range - Me (25%; 75%)). 
Parameters 
Group 1 
(n=18) 
Group 2 
(n=44) 
T1DM 
(n=62) 
Control group 
(n=10) 
Comparison 
between groups 
Р pо-к 
Minimum blood 
glucose level, 
mmol/l 
beginning 
4.2 (3.4; 4.7) 4.3 (2.2; 6.1) 
4.3 (2.75; 
5.15) 
4.05 (3.95; 
4.3) 
р=0.967 0.879 
Minimum blood 
glucose level, 
mmol/l 
after 3 months 
4.7 (2,2; 6.2) 
4.85 (3.6; 
5.4) 
4.8 (3.6; 5.4) р=0.258 0.115 
р between visits. * 0.671 0.139 0.326 - - - 
Maximum blood 
glucose level, 
mmol/l 
beginning 
13 (11; 17.5) 
16.5 (12.6; 
19.5) 
15.75 (12.3; 
18.95) 
5,65 (5,3; 
5,95) 
р<0.001 
p1-к=0.005 
p2-к<0.001 
p1-2=0.191 
<0.001 
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Table 2. Continued. 
Parameters 
Group 1 
(n=18) 
Group 2 
(n=44) 
T1DM 
(n=62) 
Control group 
(n=10) 
Comparison 
between groups 
Р pо-к 
Maximum blood 
glucose level, 
mmol/l 
after 3 months 
12.8 (10.2; 
16) 
14.8 (11.4; 
16.4) 
14.8 (11.4; 
16.1) 
 
р<0.001 
p1-к=0.006 
p2-к<0.001 
p1-2=0.694 
<0.001 
р between visits.* 0.866 0.139 0.106 - - - 
Blood glucose 
range, mmol/l 
beginning 
8.6 (6.4; 
12.7) 
10.35 (8.55; 
13.65) 
10 (7.4; 13.2) 
1.55 (1.1; 
1.85) 
р<0.001 
p1-к=0.003 
p2-к<0.001 
p1-2=0.368 
<0.001 
Blood glucose 
range, mmol/l 
after 3 months 
8.25 (6.3; 
11.4) 
10 (5.4; 
12.5) 
8.4 (5.4; 
12.5) 
р=0.001 
p1-к=0.020 
p2-к=0.001 
p1-2=0.811 
<0.001 
р between visits.* 0.327 0.085 0.054 - - - 
Notes. р – differences between groups according to the non-parametric dispersion analysis of Kruskal-Wallis (KW-H); 
aposteriori comparisons – according to the Dunn criteria, pairwise – by Mann-Whitney (U): 
p1-k - between group 1 and control group; 
p2-k – between group 2 and control group; 
ro-k – between the main group and the control group; 
p1-2 – between group 1 and group 2  
*- p in the dynamics between the beginning and after 3 months according to the Wilcoxon test 
Table 3. Albuminuria Level (mg/l), depending on the presence of hypoglycemia 
(Median and interquartile range - Me (25%; 75%)) 
Visit 
Group 1 
(n=18) 
Group 2 
(n=44) 
T1DM patients (n=62) 
hypoglycemic episode hypoglycemic episode hypoglycemic episode 
no 
(n=10) 
yes 
(n=8) 
no 
(n=25) 
yes 
(n=19) 
no 
(n=35) 
yes 
(n=27) 
Beginning 
21,7 (12,12; 
28,0) 
33,25 (21,4; 
66,18) 
29,0 (16,5; 
43,35) 
36,33 (17,1; 
60,6) 
23,5 (15,4; 
38,9) 
36,33 (20,0; 
60,6) 
р between 
groups 
0,143 0,282 0,079 
After 3 
month 
20,9 (13,8; 
24,1) 
20,25 (8,9; 
31,6) 
22,8 (19,9; 
43,7) 
28,3 (22,1; 
51,8) 
22,8 (13,8; 
43,7) 
28,3 (8,9; 
51,8) 
р between 
groups 
0,846 0,844 0,976 
Notes. р – differences between groups according to Mann-Whitney test (U). 
 
Initially the study groups did not differ by 
the frequency of hypoglycemia: 44.4% in group 
1, 43.18 % in group 2 (p=0,798) and 43.55% of 
all patients with T1DM. There were no statistical 
differences between the groups in AU level 
depending on presence of hypoglycemic 
episodes (Table 3). 
We confirmed the absence of correlation 
between the AU level and the presence of 
hypoglycemic episodes as well as the maximum 
glucose level using the rank correlation analysis 
(р>0.05).  
In group 2 there was a tendency to 
decreasing of HbA1c level (р<0.1), which was 
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10.95 (9.4; 12) % at the beginning and 9.2 (7.6; 
10) % after 3 months. At the same time, the level 
of AU significantly reduced from 34.4 (16.8; 
51.2) mg/l at the beginning of the study till 24 
(19.9; 47.6) mg/l after 3 months (р = 0.043) in 
the group with poor glucose control.  
There were no statistically significant 
changes in the blood glucose levels and the 
blood glucose range in the dynamics between the 
beginning and after 3 months (р>0, 05) 
(Table 2).  
We established the direct correlation 
between HbA1c the AU level, using the rank 
correlation method, ρ=0.29 (р<0.016) at the 
beginning and ρ=0.4 (р=0.021) after 3 months. 
The AU level has increased direct average 
correlation with maximum blood glucose level 
both at the beginning of the study and 3 months 
after the treatment modification: ρ=0.37 
(р=0,002) and ρ=0, 45 (р=0.009) respectively. 
The trend of albuminuria level at the beginning 
and after 3 months performed in Figure 1. 
 
Fig. 1. The average level of albuminuria (mg/l) in the 1st and 2nd visits in study groups (median and quarterly ranges – 
Me (25%; 75%)) 
We estimated that AU level has a direct 
correlation with blood glucose range level, at the 
beginning ρ=0.51 (р<0,001) and after 3 months 
ρ=0,48 (р=0,004).  
We decided to make a mathematical 
description of this dependence. AU did not 
appear to have normal distribution, so original 
data were transformed using an extension of the 
Box–Cox transformation with appropriate 
parameters.  
We define the change in the AU level, 
depending on blood glucose range in T1DM 
patients, using simple linear regression analysis.  
A linear regression line has an equation: 
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Y = a + bX,   (1),  
Where Y is the predicted value of the dependent variable, 
a free term in equation: is the point where the line crosses 
the Y-axis. 
an angular coefficient,  
X –a predictive variable for the calculation of the 
corresponding value Y.  
The model of the dependence between the 
AU level and blood glucose range level can be 
expressed by the equation: 
Y = 3.7817 + 0.44816 × X,    (2),  
Where X means the difference between the maximum and 
minimum blood glucose level, 
Y - is the predicted value of AU. 
The angular coefficient b = 0.4816. It means, 
that each additional unit of blood glucose range 
is accompanied by increasing an average level 
AU level by 0.4816 mg/l. 
The partial correlation coefficient and the 
determination index were calculated to assess the 
tightness of relations. Partial correlation 
coefficient is 0.54 (p<0.001); determination 
index is r
2
 =28.86%. Consequently, 28.86% 
cases of blood glucose range change lead to 
increase AU level and also 28.86% cases of AU 
level change are occurring to blood glucose 
range change. 
The remaining percentages of the Y 
variables are explained by the factors that can be 
neglected in this model.  
The validity of the regression model was 
checked using Fisher's F criterion. The model 
can be defined as valuable, according to F-test (F 
= 24.34) (p<0.001). Assessment of the 
regression models quality was performed using 
mean approximation error (mean deviation 
between calculated and actual values). The 
approximation error is 9.84% that is not higher 
than 15% so it is quite acceptable.  
A scatter diagram of the relationship 
between the blood glucose range and the AU 
level in T1DM patients is shown in Figure 2. 
 
Fig. 2. Dependence between the blood glucose range and the level of albuminuria in T1DM patients. 
Discussion 
The results of our study confirm the glucose 
control effects on the onset and progression of 
microvascular complications. The Diabetes 
Control and Complications Trial (DCCT) 
involved 1441 patients with T1DM from 1983 
till 1983. Study results showed that intensive 
therapy reduced an average AU by 39%, and 
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expressed AU by 54%, the risk of proliferative 
retinopathy by 47% [9]. 
The Epidemiology of Diabetes Interventions 
and Complications (EDIC) study involved 96% 
of DCCT participants in 1994. Findings from 
EDIC demonstrated that early and intensive 
blood glucose control lowers risks of diabetic 
kidney disease (DKD) by 50% after 18 years and 
eye surgery for diabetic retinopathy by 48% after 
17 years of DCCT completion [10,11]. 
The HBA1c variability was analyzed in 
DCCT and showed, that diabetic complications 
progression was estimated over 9 years. The 
definition of both HbA1c variability and the 
HbA1c level contributed more accurate 
prediction of microvascular complications 
development. Due to DCCT results, an increase 
HbA1c variability by 1% was associated with 
risks of retinopathy and DKD progression [9,12]. 
HbA1c is the gold standard to assess glucose 
control, but it does not involve glucose 
fluctuations. Glucose variability has been 
actively investigated after the introduction of 
continuous glucose monitors [9,13].  Although 
there was no confirmation of glucose variability 
effect on development and progression of 
diabetic complications. But some authors 
consider that determination of glucose variability 
is necessary because it’s leading to endothelial 
dysfunction and angiopathy [14-16]. 
In recent years, a large number of 
mathematical methods of glucose variability 
evaluation have been developed. Each method 
has its own peculiarities but none of them 
currently can be considered as integrated GV 
evaluation criteria. The estimation of GV had a 
number of problems in real clinical practice. 
First of all, several indexes should be 
calculated for exact GV definitions. 
Secondly, some GV parameters (MAGE, 
AUC, CONGA) specifically designed to 
evaluate GV using continuous glucose 
monitoring and appropriate software for this 
process [17]. 
We proposed the method for predicting 
onset and progression of diabetic 
microangiopathy in T1DM patients. It is not 
required any special software. The calculation 
may be performed using blood glucose self-
monitoring data in a real clinical practice. 
Conclusions 
In the first place, in our study we defined 
that increasing range glucose level as well as 
hyperglycemia has impact on the onset of DM 
microvascular complication, as an example of 
DKD.  
Secondly, we made a mathematical equation 
of dependence between AU level and blood 
glucose range using a simple linear regression 
analysis in T1DM patients that gives the 
opportunities to predict DKD progression in 
patients with T1DM.  
Thirdly, the prediction of the onset and AU 
progression in T1DM patients can be used in 
clinical practice. It helps to identify the patients 
with high risks of DKD for early start of 
treatment and make prevention of DKD 
progression. 
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